Multiple myeloma: Every year a new standard? - Rajkumar - 2019 - Hematological Oncology -
Wiley Online Library Skip to Article Content Skip to Article Information Wiley Online Library …

The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow,
leading to bone destruction and marrow failure. This manuscript discusses the management …

The large-scale genetic profiling of tumours can identify potentially actionable molecular
variants for which approved anticancer drugs are available,–. However, when patients with …

Background Anti-CD38 monoclonal antibodies have consistently shown increased efficacy
when added to standard of care for patients with multiple myeloma. We aimed to assess the …

Acknowledging the increasingly important role of whole-body MRI for directing patient care
in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical …

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …

PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …

Summary The International Myeloma Working Group consensus aimed to provide
recommendations for the optimal use of 18 fluorodeoxyglucose (18 F-FDG) PET/CT in …